Document Detail

The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.
MedLine Citation:
PMID:  23335619     Owner:  NLM     Status:  MEDLINE    
Molecularly targeted therapeutics (MTT) are the future of cancer systemic therapy. They have already moved from palliative therapy for advanced solid malignancies into the setting of curative-intent treatment for early-stage disease. Cardiotoxicity is a frequent and potentially serious adverse complication of some targeted therapies, leading to a broad range of potentially life-threatening complications, therapy discontinuation, and poor quality of life. Low-cost pleiotropic interventions are therefore urgently required to effectively prevent and/or treat MTT-induced cardiotoxicity. Aerobic exercise therapy has the unique capacity to modulate, without toxicity, multiple gene expression pathways in several organ systems, including a plethora of cardiac-specific molecular and cell-signaling pathways implicated in MTT-induced cardiac toxicity. In this review, we examine the molecular signaling of antiangiogenic and HER2-directed therapies that may underpin cardiac toxicity and the hypothesized molecular mechanisms underlying the cardioprotective properties of aerobic exercise. It is hoped that this knowledge can be used to maximize the benefits of small molecule inhibitors, while minimizing cardiac damage in patients with solid malignancies.
Jessica M Scott; Susan Lakoski; John R Mackey; Pamela S Douglas; Mark J Haykowsky; Lee W Jones
Related Documents :
10801989 - The selection and design of multiple-species habitat preserves.
25009219 - Dietary nitrate supplementation: effects on plasma nitrite and pulmonary o2 uptake dyna...
23960689 - Effects of a preoperative individualized exercise program on selected recovery variable...
25047019 - Frequency, distribution and time trends of types of leisure-time physical activity in b...
24044039 - Effects of a single low-dose acetaminophen on body temperature and running performance ...
24149749 - The effects of elapsed time after warm-up on subsequent exercise performance in a cold ...
22954509 - A novel approach for lactate threshold assessment based on rpe.
7173139 - Changes in blood neutrophil/lymphocyte ratio related to adrenocortical function in the ...
2901289 - Predicting return to work after acute myocardial infarction. significance of clinical d...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2013-01-18
Journal Detail:
Title:  The oncologist     Volume:  18     ISSN:  1549-490X     ISO Abbreviation:  Oncologist     Publication Date:  2013  
Date Detail:
Created Date:  2013-02-25     Completed Date:  2013-12-12     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  221-31     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / adverse effects,  therapeutic use
Exercise / physiology*
Heart Diseases / chemically induced*,  therapy*
Neoplasms / drug therapy,  pathology,  therapy*
Receptor, erbB-2 / administration & dosage,  antagonists & inhibitors,  metabolism,  therapeutic use*
Grant Support
Reg. No./Substance:
0/Angiogenesis Inhibitors; EC protein, human; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transcription repressor HANABA TARANU controls flower development by integrating the actions of mult...
Next Document:  The end-of-life phase of high-grade glioma patients: dying with dignity?